Cetuximab plus pemetrexed as second-line therapy for fluorouracil-based pre-treated metastatic esophageal squamous cell carcinoma

Cancer Chemotherapy and Pharmacology
Jing TianJun Xu

Abstract

The aim of this study was to evaluate the efficacy and toxicity of cetuximab and pemetrexed as the second-line treatment for advanced esophageal cancer patients, who had undergone treatment with the standard cisplatin and 5-FU regimens. A total of 29 patients accepted this treatment. Cetuximab was administered at an initial dose of 400 mg/m(2) IV followed by weekly doses of 250 mg/m(2) IV, whereas pemetrexed 500 mg/m(2) was administered on day 1 every 3 weeks. Twelve patients (41.4 %) presented PR, ten (34.5 %) had SD, and seven (24.1 %) had PD. The response rate was 41.4 %. The median PFS was 4.5 months (95 % CI 4.1-4.9), and the median OS was 9.4 months (95 % CI 8.4-10.5). The expression levels of serum miR-335 were determined, and the subsequent analysis suggested that PFS was significantly different between the patients with higher level of serum miR-335 and those with low level of serum miR-335. The former had a PFS of 4.9 months (95 % CI 4.2-5.7) and the latter 4.1 months (95 % CI 3.7-4.5) (log rank = 0.025). None of the patients experienced grade 4 toxicity. Twenty-four patients presented rash. A combination of cetuximab plus pemetrexed was marginally effective and well tolerated in patients with advanced esophageal squa...Continue Reading

References

Aug 23, 2002·Annals of Surgery·Wayne HofstetterJack A Roth
May 21, 2004·Annals of Oncology : Official Journal of the European Society for Medical Oncology·K MuroT Ohtsu
Feb 10, 2006·The New England Journal of Medicine·James A BonnerK Kian Ang
Feb 20, 2007·Molecular Cancer Therapeutics·Shrikanta ChattopadhyayI David Goldman
Jun 5, 2007·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Zhongxing LiaoRitsuko Komaki
Nov 6, 2007·International Journal of Radiation Oncology, Biology, Physics·Howard SafranTeresa Kennedy
Jan 29, 2008·Cancer Metastasis Reviews·K N SyrigosMuhammad Wasif Saif
Mar 20, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Salah-Eddin Al-BatranUNKNOWN Arbeitsgemeinschaft Internistische Onkologie
Jun 23, 2009·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Jianhua JinDaoyuan Wang
Oct 27, 2010·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Aminah JatoiSteven R Alberts
Nov 16, 2010·Diseases of the Esophagus : Official Journal of the International Society for Diseases of the Esophagus·Bao-Sheng LiJ-M Yu
Jan 11, 2011·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J A ChanC S Fuchs
Jan 20, 2011·Journal of Gastrointestinal Surgery : Official Journal of the Society for Surgery of the Alimentary Tract·Richard HummelDamian J Hussey
Jun 21, 2011·CA: a Cancer Journal for Clinicians·Rebecca SiegelAhmedin Jemal
Nov 10, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Christiane Maria Rosina ThallingerMichael Hejna
Jun 19, 2012·Journal of Molecular Medicine : Official Organ of the Gesellschaft Deutscher Naturforscher Und Ärzte·Niamh Lynam-LennonStephen G Maher
Apr 19, 2013·The Lancet Oncology·Florian LordickUNKNOWN Arbeitsgemeinschaft Internistische Onkologie and EXPAND Investigators
Aug 30, 2014·Asian Pacific Journal of Cancer Prevention : APJCP·Wen-Rui TangKun Lin
Oct 24, 2014·Asian Pacific Journal of Cancer Prevention : APJCP·Guang-Yu TianXin-En Huang

❮ Previous
Next ❯

Citations

Feb 20, 2016·Expert Review of Gastroenterology & Hepatology·Lei ZhangDaiming Fan
Aug 26, 2017·Expert Review of Gastroenterology & Hepatology·Wanli YangLiu Hong
Dec 26, 2018·Expert Review of Molecular Diagnostics·Wanli YangDaiming Fan

❮ Previous
Next ❯

Related Concepts

Related Feeds

Carcinoma, Squamous Cell

Basal cell carcinoma is a form of malignant skin cancer found on the head and neck regions and has low rates of metastasis. Discover the latest research on basal cell carcinoma here.